We are live on ! Find out more
TCP

Tyndall Capital Partners Portfolio holdings

AUM $452K
1-Year Est. Return 26.52%
This Fund
S&P 500
This Quarter Est. Return
+6.07%
1 Year Est. Return
+26.52%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.32M
AUM Growth
-$388K
Cap. Flow
-$524K
Cap. Flow %
-22.58%
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
–
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
TRAW icon
Traws Pharma
TRAW
+$524K

Sector Composition

Rank Sector Weight
1 Financials 99.4%
2 Miscellaneous 0.6%
3 Healthcare 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MMAC
1
DELISTED
MMA Capital Holdings, Inc. Common Stock
MMAC
$2.31M 99.4%
72,552
– –
ONTXW
2
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$14K 0.6%
390,624
– –
TRAW icon
3
Traws Pharma
TRAW
$9.17M
– –
-1,644
Closed -$524K

Similar funds

CCM
Cota Capital Management San Francisco, California $177K AUM 63.94% 1-Year Est. Return
HIP
Hatteras Investment Partners Raleigh, North Carolina $169K AUM 86.49% 1-Year Est. Return
BPWM
Black Point Wealth Management Naples, Florida $3.5M AUM 16.42% 1-Year Est. Return
NP
Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return
CP
Castalian Partners Excelsior, Minnesota $7.36M AUM
AI
Allostery Investments Stamford, Connecticut $7.85M AUM
CAWM
Capital A Wealth Management New Castle, Pennsylvania $8.94M AUM
ADIM
Alpha DNA Investment Management Columbia, Maryland $8.98M AUM 26.05% 1-Year Est. Return

Tyndall Capital Partners's Q4 2019 Portfolio in Review

As of Q4 2019, Tyndall Capital Partners held 3 positions worth $2.32M, down 14% from $2.71M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Tyndall Capital Partners withdrew a net $524K in Q4 2019, closing 1 position. Its most notable exit was Traws Pharma, an estimated $524K position sold in full.

By sector, the portfolio is most concentrated in Financials at 99% of assets, up from 80% a quarter earlier, followed by Miscellaneous and Healthcare.

  • Tyndall Capital Partners fully exited Traws Pharma in Q4 2019, selling an estimated $524K.
  • Tyndall Capital Partners's ten largest holdings make up 100% of its $2.32M portfolio in Q4 2019.
  • Tyndall Capital Partners opened 0 new positions and closed 1 in Q4 2019.
  • Tyndall Capital Partners's portfolio value fell 14% quarter-over-quarter to $2.32M.

Based on Tyndall Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.